We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

WATERS CORPORATION

Waters Corp. designs, manufactures, sells and services ultra performance liquid chromatography (UPLC), high performan... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Low Serotonin Levels Associated with Higher Nigral Iron in Parkinson’s Disease

By LabMedica International staff writers
Posted on 17 Jan 2022
Print article
Image: The Water’s Xevo triple-quadrupole mass spectrometry (TQ-S MS/MS) system (Photo courtesy of Duke University)
Image: The Water’s Xevo triple-quadrupole mass spectrometry (TQ-S MS/MS) system (Photo courtesy of Duke University)
Parkinson’s disease (PD) is a neurodegenerative disorder characterized clinically by bradykinesia, rigidity, and/or tremor and pathologically by dopaminergic neuron loss in the substantia nigra pars compacta (SNc) and the presence of ⍺-synuclein-containing inclusions in cell bodies or neurites (Lewy pathology).

Iron accumulation in the brain is common with aging and consistently reported to be increased in PD, particularly in the substantia nigra (and specifically the SNc). Low serotonin is thought to contribute to the high rate (~ 35%) of clinically significant depression, an often prodromal symptom, among patients. Lower CSF serotonin also has been associated with freezing of gait.

A team of Neurologist at Pennsylvania State University (Hershey, PA, USA) and their associates investigated whether lower plasma serotonin in PD is associated with higher nigral iron. They obtained plasma samples from 97 PD patients and 89 controls and MRI scans from a sub-cohort (62 PD, 70 controls).

For analysis of peripheral serum iron metrics (red blood cell count, hemoglobin, hematocrit, serum iron, transferrin, total iron binding capacity (TIBC), transferrin saturation) and platelet counts, blood was collected into a BD PST II plasma separator tube (Becton, Dickinson and Company, Franklin Lakes, NJ , USA), and analyzed by using standard assays.

Plasma serotonin concentrations were measured using an Acuity ultra-high-performance liquid chromatography (UPLC) I class and Xevo triple-quadrupole mass spectrometry (TQ-S MS/MS) system (Waters, Milford, MA, USA). Brain MRI scans were offered to all subjects, but completed by only a subset (70 controls, 62 PD patients) and were used for regional iron content using MRI-based quantitative susceptibility mapping.

The investigators reported that PD patients had lower mean plasma serotonin concentrations than controls [in log scale, 5.53 ± 1.40 versus 6.25 ± 0.85, P < 0.0001] and higher nigral iron content (SNc: p < 0.001) overall. The correlation appeared strongest in patients during the first year of diagnosis but waned in later stage disease, when an increasing number of influences on these features presumably come into play. However, the PD distribution appeared distinctly bimodal, and the group difference was driven by approximately one-third of patients with extremely low concentrations (the lowest tertile, n = 32; < 150 nM). In the remaining two-thirds of PD patients, plasma serotonin concentrations were distributed relatively widely and within the normal range of controls.

The authors concluded that there was a robust correlation between low plasma serotonin and higher iron content in the SNc in PD, which was absent in controls. This correlation was present even in patients within one year of diagnosis, suggesting it might also be present in the prodromal phase, and was stronger in the SNc than any other brain region examined. The study was published on December 21, 2021 in the journal Scientific Reports.

Related Links:
Pennsylvania State University
Becton, Dickinson and Company
Waters


Gold Supplier
TBI Blood Test
i-STAT TBI Plasma Test
New
Electrolyte Analyzer
CARELYTE A-Series
New
Automatic Immunoassay Analyzer
PATHFAST
New
Gold Supplier
Chemistry Analyzer
BS-600M

Print article

Channels

Molecular Diagnostics

view channel
Image: Researchers have identified 10 new genes linked with hearing loss (Photo courtesy of 123rf.com)

Newly Identified Genes May Help to Screen and Treat Individuals with Hearing Loss

A massive genome-wide association study (GWAS) identified 10 novel gene loci associated with hearing loss, which may aid in screening and treating the disorder. Hearing loss is one of the top contributors... Read more

Hematology

view channel
Image: The CS-2500 analyzer features pre-analytic sample checks and four detection methods simultaneously on a single platform – coagulation end-point, chromogenic kinetic analysis, turbidimetric immunoassay and automated platelet aggregation (Photo courtesy of Sysmex)

Microvascular/Endothelial Dysfunction Contributes to Post-COVID Syndrome Pathogenesis

Post-COVID syndrome (PCS) or Long-COVID is an increasingly recognized complication of acute SARS-CoV-2 infection, characterized by persistent fatigue, reduced exercise tolerance chest pain, shortness of... Read more

Industry

view channel
Image: Sales of lateral flow assays in clinical testing are expected to register a CAGR of 5% through 2032 (Photo courtesy of Pexels)

Global Lateral Flow Assays Market to Surpass USD 11.5 Billion by 2032 Due to Evolving Applications

The global lateral flow assays market was valued at USD 7.2 billion in 2021 and is projected to register a CAGR of 4.7% during 2022-2032 to surpass USD 11.7 billion by the end of 2032, driven by the growing... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.